BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23145146)

  • 21. A novel RET rearrangement (ACBD5/RET) by pericentric inversion, inv(10)(p12.1;q11.2), in papillary thyroid cancer from an atomic bomb survivor exposed to high-dose radiation.
    Hamatani K; Eguchi H; Koyama K; Mukai M; Nakachi K; Kusunoki Y
    Oncol Rep; 2014 Nov; 32(5):1809-14. PubMed ID: 25175022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The RET oncogene in papillary thyroid carcinoma.
    Prescott JD; Zeiger MA
    Cancer; 2015 Jul; 121(13):2137-46. PubMed ID: 25731779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
    Ma Y; Qin H; Cui Y
    Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
    Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
    Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma.
    Sozzi G; Bongarzone I; Miozzo M; Borrello MG; Blutti MG; Pilotti S; Della Porta G; Pierotti MA
    Genes Chromosomes Cancer; 1994 Apr; 9(4):244-50. PubMed ID: 7519046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pitfalls in RET Fusion Detection Using Break-Apart FISH Probes in Papillary Thyroid Carcinoma.
    Liu Y; Wu S; Zhou L; Guo Y; Zeng X
    J Clin Endocrinol Metab; 2021 Mar; 106(4):1129-1138. PubMed ID: 33382428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer.
    Raman R; Villefranc JA; Ullmann TM; Thiesmeyer J; Anelli V; Yao J; Hurley JR; Pauli C; Bareja R; Wha Eng K; Dorsaint P; Wilkes DC; Beg S; Kudman S; Shaw R; Churchill M; Ahmed A; Keefer L; Misner I; Nichol D; Gumpeni N; Scognamiglio T; Rubin MA; Grandori C; Solomon JP; Song W; Mosquera JM; Dephoure N; Sboner A; Elemento O; Houvras Y
    J Exp Med; 2022 Jun; 219(6):. PubMed ID: 35510953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.
    Wang C; Mayer JA; Mazumdar A; Brown PH
    Breast Cancer Res Treat; 2012 Jun; 133(2):487-500. PubMed ID: 21947652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.
    Santoro M; Melillo RM; Fusco A
    Eur J Endocrinol; 2006 Nov; 155(5):645-53. PubMed ID: 17062879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.
    De Falco V; Castellone MD; De Vita G; Cirafici AM; Hershman JM; Guerrero C; Fusco A; Melillo RM; Santoro M
    Cancer Res; 2007 Jan; 67(1):381-90. PubMed ID: 17210721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [RET/PTC Gene Rearrangements in the Sporadic and Radiogenic Thyroid Tumors: Molecular Genetics, Radiobiology and Molecular Epidemiology].
    Ushenkova LN; Koterov AN; Biryukov AP
    Radiats Biol Radioecol; 2015; 55(3):229-49. PubMed ID: 26310016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
    Kumarasamy VM; Sun D
    Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes.
    Celestino R; Sigstad E; Løvf M; Thomassen GO; Grøholt KK; Jørgensen LH; Berner A; Castro P; Lothe RA; Bjøro T; Sobrinho-Simões M; Soares P; Skotheim RI
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1154-64. PubMed ID: 22961909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of RET gene mediated EGFR signaling pathway on epithelial-mesenchymal transition, proliferation and apoptosis of papillary thyroid carcinoma cells.
    Zhao YL; Yuan BQ; Shen GS
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8036-8047. PubMed ID: 32767330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [
    Zhang X; Su X; Chen WC; Li Y; Yang ZY; Deng WZ; Deng TC; Yang AK
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 52(6):435-439. PubMed ID: 28635216
    [No Abstract]   [Full Text] [Related]  

  • 38. Creation and characterization of a doxycycline-inducible mouse model of thyroid-targeted RET/PTC1 oncogene and luciferase reporter gene coexpression.
    Knostman KA; Venkateswaran A; Zimmerman B; Capen CC; Jhiang SM
    Thyroid; 2007 Dec; 17(12):1181-8. PubMed ID: 18004977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in Thyroid Cancers of Young Patients in Fukushima.
    Iyama K; Matsuse M; Mitsutake N; Rogounovitch T; Saenko V; Suzuki K; Ashizawa M; Ookouchi C; Suzuki S; Mizunuma H; Fukushima T; Suzuki S; Yamashita S
    Thyroid; 2017 Jun; 27(6):811-818. PubMed ID: 28351223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells.
    Gilbert-Sirieix M; Ripoche H; Malvy C; Massaad-Massade L
    Thyroid; 2010 Oct; 20(10):1053-65. PubMed ID: 20615140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.